Journal of Cataract & Refractive Surgery

Visual and Refractive Outcomes after Bilateral Implantation of an Enhanced Monofocal IOL: a Prospective study

--Manuscript Draft--

Manuscript Number:	JCRS-23-531R3
Article Type:	Full Length Article
Section/Category:	Cataract
Full Title:	Visual and Refractive Outcomes after Bilateral Implantation of an Enhanced Monofocal IOL: a Prospective study
Corresponding Author:	Celia Villanueva Hospital Clínico San Carlos Madrid, Madrid SPAIN
First Author:	Javier García-Bella
Order of Authors:	Javier García-Bella
	Bárbara Burgos-Blasco
	Beatriz Vidal-Villegas
	Nuria Garzón
	Celia Villanueva
	Julián García-Feijoo
Abstract:	Purpose: To evaluate visual and refractive outcomes, as well as patient satisfaction after bilateral implantation of an enhanced monofocal intraocular lens (IOL) with emmetropia as a target refraction. Setting: San Carlos Hospital, Madrid, Spain. Design: Prospective, monocentric, non-comparative study. Methods: Adults 21 years or older suitable for cataract surgery and with corneal astigmatism < 1.50D were bilaterally implanted with the RayOne EMV IOL and followed up for 3-months. Outcomes measures included refraction, monocular and binocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), distance corrected intermediate visual acuity (DCIVA), and defocus curve, aberrometry, and satisfaction. Visual symptoms were assessed using the CatQuest-9SF questionnaire. Results: 50 eyes of 25 patients were included. At Month-3, the mean manifest spherical equivalent was -0.39 ± 0.28 D, with all eyes within 1.00 D. Binocularly, uncorrected, at distance, 68% of patients could read ≤ 0.0 logMAR and 95% ≤ 0.2 logMAR; at intermediate 59% of patients could read ≤0.1 and 100% ≤ 0.2 logMAR. Mean monocular CDVA was -0.03 ± 0.06 logMAR and mean monocular DCIVA was 0.28 ± 0.07 logMAR. Binocular defocus curve demonstrated a visual acuity ≤ 0.2 logMAR over a 2 D range from +1.00 D to -1.25 D. Satisfaction was good in 96% of patients. Conclusion: Bilateral implantation of an enhanced monofocal IOL with emmetropia as a target provided excellent binocular CDVA and good DCIVA, with a high level of satisfaction.
Keywords:	Cataract; Intraocular lens; Enhanced monofocal; Visual Outcomes.

Journal of Cataract & Refractive Surgery

Visual and Refractive Outcomes after Bilateral Implantation of an Enhanced Monofocal IOL: a Prospective study.

JCRS-23-531R2

Dear Editor,

First of all, we would like to thank the Reviewers for their high quality and constructive review of our manuscript, and the Editor for his careful reading.
In this revised version of the manuscript, we did our best to address all comments raised by the Reviewer 1. We thank both reviewers for the time and effort and for the invaluable help in improving our work.
All named authors approve this revised version.

Please, find below our responses in blue to the reviewers' comments:

> Reviewer #1: I am puzzled by the authors' fixation on uncorrected visual acuities. This is a nice study on an important topic. I simply recommend that the authors focus much more of their attention on distance-corrected intermediate acuity, particularly in the discussion section of the manuscript, and that they greatly deemphasize the discussion of uncorrected acuities.
>
> The true test of an extended-range-of-vision IOL is distance-corrected acuity. The authors do report distance-corrected intermediate visual acuity, but it is mentioned with only one sentence in the discussion section of the paper. Instead, they spend a lot of time discussing uncorrected acuities, which, as we have pointed out previously, are subject to variation as a function of uncorrected refractive error.

Response: Thank you for your comment. In response to your request, we have made the following changes:

- **Abstract**: we have added the CDVA and DCIVA in the Results section of the Abstract, and modified the Abstract conclusion to include the corrected visions.
- **Discussion**: on page 12, we reduced the section on Uncorrected Distance Visual Acuity. It now just state that the values in this study were comparable to other published studies for advance monofocal IOLs, such as the lens under study. .

  The section on Uncorrected Intermediate Visual Acuity (p12) was removed completely.

  A new section on Distance Corrected Intermediate Visual Acuity was added instead, including a comparison to the Isopure and Eyhance IOLs.
- **The Conclusion** has also been modified to include the corrected distance and intermediate visual acuities (p15)

We hope that our response will be satisfactory to the reviewers,

TITLE

Visual and Refractive Outcomes after Bilateral Implantation of an Enhanced Monofocal IOL: a Prospective study.

ABSTRACT

Purpose: To evaluate visual and refractive outcomes, as well as patient satisfaction after bilateral implantation of an enhanced monofocal intraocular lens (IOL) with emmetropia as a target refraction.

Setting: San Carlos Hospital, Madrid, Spain.

Design: Prospective, monocentric, non-comparative study.

Methods: Adults 21 years or older suitable for cataract surgery and with corneal astigmatism < 1.50D were bilaterally implanted with the RayOne EMV IOL and followed up for 3-months. Outcomes measures included refraction, monocular and binocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), distance corrected intermediate visual acuity (DCIVA), and defocus curve, aberrometry, and satisfaction. Visual symptoms were assessed using the CatQuest-9SF questionnaire.

Results: 50 eyes of 25 patients were included. At Month-3, the mean manifest spherical equivalent was -0.39 ± 0.28 D, with all eyes within 1.00 D. Binocularly, uncorrected, at distance, ~~mean UDVA was 0.01 ± 0.08 logMAR with~~ 68% of patients could read ≤ ~~20/20~~0.0 logMAR ~~or better~~ and 95% ≤ ~~20/32~~0.2 logMAR ~~or better;~~. at intermediate ~~Mean binocular UIVA was 0.13 ± 0.07 logMAR with~~ 59% of patients could read ≤~~20/25~~0.1 ~~or better~~ and 100% ≤ ~~20/32~~0.2 logMAR ~~or better~~. Mean monocular CDVA was -0.03 ± 0.06 logMAR and mean monocular DCIVA was 0.28 ± 0.07 logMAR. Binocular defocus curve demonstrated a ~~ly,~~

visual acuity ≤ ~~was 20/32~~0.2 logMAR ~~or better~~ over a 2 D range from +1.00 D to -1.25 D. Satisfaction was good in 96% of patients.

Conclusion: Bilateral implantation of an enhanced monofocal IOL with emmetropia as a target provided excellent binocular CDVA and good DCIVA, with ~~unaided distance and intermediate vision and~~ a high level of satisfaction. ~~A small residual myopic refraction was beneficial and allowed a gain of 1 line of visual acuity at intermediate, without reducing distance visual acuity~~.

INTRODUCTION

The standard of care in cataract surgery is changing with the continuous development of presbyopia-correcting IOLs as well as the increasing patients' demand for restoration of functional vision at all distances. Increased spectacle independence has resulted in an increase in quality of life after surgery[1] as well as increased patient satisfaction.[2-4]

Monofocal IOLs are commonly implanted and provide good distance vision and minimal visual disturbances; however, monofocal IOLs are not designed to offer spectacle independence at near or intermediate. On the other hand, multifocal IOLs have been shown to provide acceptable visual acuity from distance to near, however, their main disadvantages remain a loss in contrast sensitivity and increased visual disturbances such as halos and glare.[5]

Extended depth of focus (EDoF) IOLs have been developed with the aim of providing patients with a continuous range of good vision from distance to intermediate, while limiting dysphotopsia.[6, 7] Instead of splitting the focusing light into separate focal points, these lenses create a single elongated focal point to enhance the depth of focus, improving intermediate vision without compromising distance vision.[8, 9] However, the performance of diffractive EDoF IOLs still has limitations, including reduced quality of vision.

Non-diffractive enhanced monofocal IOLs share a similar objective of primarily optimising distance vision while extending the range of vision toward the intermediate range, but without compromising quality of vision and binocular distance vision. Non-diffractive elongation of the depth-of-focus, can be achieved through various methods such as small apertures, wavefront shaping technologies, or manipulations of spherical aberrations.[10]

Amongst these, the RayOne EMV RAO200E lens (Rayner Intraocular Lenses Limited, Worthing, UK) is a non-diffractive, monofocal aspheric lens, designed to extend the range of vision by inducing a controlled amount of positive spherical aberrations, unlike other

technologies using negative spherical aberration. The aim of this study was to evaluate refractive and visual outcomes as well as patient satisfaction after bilateral implantation of the RayOne EMV RAO200E.

METHODS

This prospective, single centre, observational, non-comparative study was performed at San Carlos Hospital, in Madrid Spain. The study was reviewed and approved by the hospital's Ethics Committee (Reference 21/664-O_P). Written informed consent was obtained from all patients preoperatively, after they were fully informed about the purpose of the study. The study followed the tenets of the Declaration of Helsinki.

Patients included in the study were men and women aged 21 years or older who presented with bilateral cataract and suitable for cataract surgery with bilateral implantation of the RayOne EMV IOL. Other inclusion criteria were: preoperative corneal astigmatism < 1.50D, potential for best-corrected distance visual acuity (CDVA) of 0.18 logMAR or better postoperatively, and calculated IOL power in the range of +10.0 D to +30.0 D. Subjects were excluded from participation if they suffered from other co-morbidity such as other medical or ocular conditions that could affect the outcome. Eyes with preoperative corneal positive spherical aberration greater than 0.40 µm for a 6-mm pupil were excluded.

Patients attended a preoperative visit, and three postoperative visits: 1 to 2 days after surgery (Day-1), 30 to 60 days after surgery (Month-1), and 100 to 120 days after surgery (Month-3).

Intraocular lens

The CE-marked RayOne EMV RAO200E lens (Rayner Intraocular Lenses Limited, Worthing, UK) is made of Rayacryl hydrophilic acrylic; it is a non-diffractive enhanced monofocal aspheric IOL. The centre of the optics induces controlled positive spherical aberration (maximum 0.15 µm across the 6-mm optic) to spread light along the visual axis and elongate

the focal range from far into intermediate and the blended edge reduces longitudinal spherical aberration to maintain visual acuity and contrast sensitivity in mesopic conditions. It has a refractive index of 1.46 and an Abbe number of 56.[11]

The IOL is fully preloaded in the RayOne injector in the full power range (+10.0 D to +30.0 D in 0.5 D increments) and allows implantation through a 2.2 mm incision. The injector features a syringe-shaped design to allow for a one-handed IOL placement technique.

Surgical Procedure

The surgery was performed as per the surgeon preferred micro-incision surgical technique under topical anesthesia, using standard phacoemulsification and a 2.2 mm incision.

Biometry was measured using the IOL master 700 (Carl Zeiss Meditec, Jena, Germany). IOL power was calculated using the Barrett Universal II Formula (lens factor 1.67; design factor 3.5) and the manufacturer suggested A-constant of 118.6. The target refraction was emmetropia for both eyes; the IOL power was selected as the IOL power resulting in the smallest postoperative myopic refraction (i.e., the closest myopic refraction to zero), rather than resulting in the refraction closest to zero.

Postoperative medication was prescribed according to hospital protocol, including topical antibiotics and steroids.

Preoperative and Postoperative Assessments

Visual acuity was measured using ETDRS charts, with 100% contrast, under photopic conditions and reported in logMAR. Uncorrected distance visual acuity (UDVA) and CDVA were measured monocularly and binocularly at 4 meters. Uncorrected intermediate visual acuity (UIVA) and distance corrected intermediate visual acuity (DCIVA) were measured monocularly and binocularly at 66 cm. DCIVA was measured with the distance manifest

refraction in place as per recommended published standards.[12] Visual acuities were measured at 1-month and 3-month visits.

Defocus curve was performed with the manifest refraction in place, monocularly (at the 1-month visit) and binocularly (at the 3-month visit) under photopic conditions (85 cd/m^2), with defocus values between +1.00 D to -2.50 D in 0.50 D steps.

Pupillometry was measured using the KR-1W wavefront analyser (Topcon, Tokyo, Japan).

Preoperatively, corneal aberrations were measured with the Pentacam (Oculus GmbH, Wetzlar, Germany) for the 6 mm pupil diameter. Postoperatively, corneal and ocular aberrations were measured with the Hartmann-Shack KR-1W wavefront analyser.

Patient satisfaction and spectacle independence were measured using the validated CatQuest-9SF questionnaire.

Aberrometry and questionnaires were performed at 3-month visit.

Adverse events were recorded at all visits.

Statistical Analysis

Sample size was calculated using published results related to UIVA by Kang et al.[13] Given an alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test, it was calculated that 25 subjects were required to achieve a statistically significant difference greater than or equal to 0.06 logMAR units. The standard deviation was assumed to be 0.1. It had been anticipated a drop-out rate of 10%.

Data analysis was performed with the SPSS software for Windows, version 26.0 (IBM, Armonk, NY, USA). The study data were analysed using descriptive statistics including mean and standard deviation (SD) for each parameter. For each study metric, normality was analysed using the Shapiro-Wilk test. When parametric analysis was possible, t test for paired data was

used to compare results between consecutive visits. When parametric analysis was not possible, the Wilcoxon test was used to compare parameters across visits. For all statistical tests, a p-value of less than 0.05 was considered to be statistically significant.

Only the right eye of each patient was included in the analysis of refraction and monocular visual acuity.

RESULTS

A total of 25 patients (50 eyes) were included and bilaterally implanted with the EMV IOL. All patients completed the 3-Month follow-up. Mean preoperative characteristics are described in Table 1.

Refractive Results

Postoperative mean spherical equivalent (SEQ) was -0.47 ± 0.39 D (-1.75 D to 0.00 D) at Month-1 and -0.39 ± 0.28 D (-1.00 D to 0.25 D) at Month-3. Figure 1A shows the distribution of the SEQ at Month-3: 87.0% of eyes were within ±0.50 D and 100% of eyes within ±1.00 D of emmetropia.

Postoperative astigmatism was -0.50 ± 0.44 D (-1.50 D to 0.00 D) at Month-1 and -0.52 ± 0.44 D (-1.25 D to 0.00 D) at Month-3. Figure 1B shows the distribution of refractive astigmatism at Month-3: 60.9% of eyes were within ±0.50 D and 87.0% of eyes within ±1.00 D of target.

Visual Acuity Results

Mean visual acuity values are shown in Table 2.

All eyes had a monocular CDVA of 0.06 logMAR or better, except one eye diagnosed with macular edema at the 1-month visit and persisting at the 3-month visit with a CDVA of 0.3 logMAR.

Figure 1C shows the distribution of the difference between postoperative monocular UDVA and postoperative monocular CDVA; UDVA was within 1 line of CDVA for 92% of eyes.

Mean monocular UDVA (at 4 m) was 0.06 ± 0.11 logMAR at Month-3. As shown on Figure 2A, at Month-3, UDVA was 0.0 logMAR or better in 58% of eyes, 0.1 logMAR or better in 88% of eyes, and 0.2 logMAR or better in 96% of eyes. Binocularly (Figure 2C), UDVA was 0.1 logMAR or better in 95% of patients, and 0.2 logMAR or better in all patients.

At Month-3, mean monocular UIVA (at 66 cm) was 0.19 ± 0.09 logMAR; UIVA was 0.1 logMAR or better in 35% of eyes, 0.2 logMAR or better in 78%, and 0.3 logMAR or better in 96% of eyes (Figure 2B). Binocularly (Figure 2D), UIVA was 0.1 logMAR or better in 59% of patients and 0.2 logMAR or better in all patients.

At Month-3, mean monocular DCIVA was 0.28 ± 0.07 logMAR. As shown on Figure 2B, DCIVA was 0.1 logMAR or better in 4% of eyes, 0.2 logMAR or better in 39%, and 0.3 logMAR or better in 91% of eyes. Binocularly (Figure 2D), DCIVA was 0.1 logMAR or better in 23% of patients, 0.2 logMAR or better in 59% of patients, and 0.3 logMAR or better in 86% of patients.

Defocus Curve

The distance corrected monocular and binocular defocus curves (Figure 3) showed a peak at defocus 0.00 D (4 m) and as expected, a gradual continuous reduction in visual acuity with the increase in negative defocus (near vision). For a defocus of -1.50 D (equivalent to a 66 cm viewing distance), mean visual acuity was 0.36 ± 0.12 logMAR monocularly and 0.24 ± 0.09 binocularly.

Questionnaires

Figure 4 shows the results of the CatQuest-9SF questionnaire obtained at Month-3. Most patients (92%) reported that their vision did not cause any difficulty in their everyday life. In

terms of satisfaction, 58% of patients reported being very satisfied with their present vision and 38% of patients reported being fairly satisfied. In terms of difficulties with everyday tasks, most patients (between 80% and 96%) reported no difficulty with recognizing faces, seeing prices of goods when shopping, seeing to walk on uneven ground, seeing to do needlework and handicraft, reading text on television, and seeing to carry out a preferred hobby. For reading text in newspaper, 58% of patients reported no difficulty, 37% reported some difficulty, and 4% reporting great difficulties. No patient reported being very dissatisfied or having very great difficulties for any questions.

Corneal and Ocular Aberrations

Mean preoperative and 3-month postoperative corneal and ocular spherical aberrations are presented in Supplemental Table 1. There was no statistically significant change in corneal spherical aberrations after surgery for the 4 mm pupil ($p=0.105$) and 6 mm pupil ($p=0.057$). There was a statistically significant increase in ocular spherical aberrations ($p<0.001$) for both the 4-mm pupil (from 0.04 ± 0.11 µm to 0.10 ± 0.04 µm) and the 6-mm pupil (from 0.07 ± 0.40 µm to 0.38 ± 0.17 µm) induced by the RayOne EMV IOL.

Adverse Events

Three non-serious adverse events were identified, all cystoid macular oedema. One was experienced monocularly, and the other two occurred in the same patient. Two adverse events resolved before the 1-month visit. In the third eye, despite apparent resolution on OCT, loss of CDVA persisted at month-1 and month-3 (CDVA of 0.30 logMAR). A subsequent visit showed improvement in CDVA, suggesting unresolved CME at month-3. Consequently, this eye was excluded from the visual and refractive outcomes analysis.

There were no intraoperative adverse events.

DISCUSSION

The RayOne EMV is the only enhanced monofocal IOL on the market using positive spherical aberration rather than negative spherical aberration to increase depth of focus. Regarding presbyopic-correction strategies using induced aberrations for increased depth of focus, Bakaraju et al.[14] reported that both positive and negative spherical aberration have equal potential. The IOL was designed so that the induced positive spherical aberration complements the natural positive spherical aberration of the human cornea. An equivalent negative spherical aberration IOL needs to first negate the positive spherical aberration of the cornea, then add even more negative spherical aberration to induce any required depth of focus improvements. The total spherical aberration used on the RayOne EMV is therefore designed to be significantly less than for equivalent negative spherical aberration extended depth IOLs. Using optical bench analysis, Schmid et al.[15] confirmed a positive increase in spherical aberration, as per the manufacturer's claim. Our clinical study corroborated that the RayOne EMV IOL induces positive spherical aberration in implanted eyes. Corneal aberrations remained unchanged after surgery, however ocular spherical aberrations positively increased postoperatively, averaging 0.38 ± 0.17 µm (range: 0.02 µm to 0.72 µm) for the 6-mm pupil.

The increase in spherical aberration was also significant for the 4-mm pupil, increasing from 0.04 ± 0.11 µm before surgery to 0.10 ± 0.04 µm after surgery. This is important as a 4 mm pupil diameter closely aligns with the average pupil size of 3.6 mm measured under photopic conditions in our study. This supports the finding that the improvement in intermediate vision is due to the increased depth of field resulting from the increase in spherical aberration.

At the time of writing, there are only published studies assessing the optical quality of the RayOne EMV using optical bench evaluation. This is the first in humans' study reporting the visual and refractive outcomes of patients implanted with the RayOne EMV. Schmid et al.[16]

compared 4 enhanced monofocal IOLs in an optical bench study and concluded that for a small aperture, the peak modulation transfer function was best for the Eyhance IOL (Johnson & Johnson Vision, Santa Ana, USA) and RayOne EMV indicating excellent distance quality of vision. Alarcon et al.[17] also performed optical bench testing to evaluate the distance image quality of three enhanced monofocal IOLs including the RayOne EMV. The simulated visual acuity demonstrated that the RayOne EMV provided as good distance vision as that of a standard monofocal; both papers are in good agreement with the clinical findings in our study where mean CDVA was excellent and slightly better than 20/20 (-0.03 ± 0.06 logMAR).

In the absence of previously published clinical data on the RayOne EMV, we compared our results with published literature on other non-diffractive enhanced monofocal IOLs, also offering an increased range of vision,[18] including the Tecnis Eyhance ICB00 (Johnson & Johnson Vision, Santa Ana, USA), and the ISOPURE 1.2.3 (PhysIOL S.A, Liege, Belgium). Given that the spherical aberration of any optical system is dependent on the height of incoming light rays with respect to the optic axis, and therefore on the diameter of the entrance pupil of the system, it is important to understand the strategies used by the manufacturers to increase the depth of focus with these IOLs. It should be considered that positive spherical aberration induces an extra positive power in the lens periphery compared to its central zone. Conversely, negative spherical aberration leads to greater power in the central zone.

In our study, refractive accuracy was excellent with 87% of eyes within ±0.50 D and all eyes within ±1.00 D of target. These results are consistent with published data on other enhanced monofocal IOLs. In our study, most eyes were slightly myopic postoperatively (mean postoperative SEQ: -0.36 ± 0.28 D) aligning with the preference for a small myopic postoperative target over a hypermetropic one while targeting emmetropia in all eyes. The small postoperative myopic spherical equivalent did not greatly affect uncorrected visual acuity; mean binocular uncorrected distance vision at 3-months after surgery was good (0.01 ±

0.08 logMAR) with 68% of patients reaching 0.0 logMAR or better, and 95% reaching 0.1 logMAR or better. ~~However, the small myopic refraction was beneficial for uncorrected vision at intermediate, improving intermediate vision of 1 line when measured uncorrected (UIVA) compared to corrected with the distance manifest refraction (DCIVA).~~

Binocular UDVA in our study (0.01 ± 0.08 logMAR) was comparable to previously reported for other IOLs: 0.03 ± 0.12 logMAR for the Eyhance ~~Auffarth et al.~~[18] and -0.02 ± 0.13 logMAR for the Isopure ~~assessed binocular UDVA after implantation with the Eyhance and reported a similar mean value of 0.03 ± 0.12 logMAR. Stodulka et al.~~[19] ~~reported mean binocular UDVA of -0.02 logMAR after implantation with the Isopure, which is half a line better~~.

~~At intermediate distance, there were small differences of less than 1 line of visual acuity between the different IOLs. Binocular UIVA measured at 66 cm was slightly better with the Eyhance IOL; Lee et al. ADDIN EN.CITE ADDIN EN.CITE.DATA~~ [20] ~~reported a mean value of 0.08 ± 0.11 logMAR. In our study, mean UIVA was 0.13 ± 0.07 logMAR which is between half a line and a line less than the Eyhance. On the other hand, binocular UIVA with the EMV was between half a line and one line better than that of the Isopure (0.20 ± 0.14 logMAR). Stodulka et al.~~ [19] ~~reported that 35% of patients with binocular UIVA of 0.1 logMAR or better and 82% 0.2 logMAR or better. This is similar to our results with the EMV showing 59% of patients with binocular UIVA of 0.1 logMAR or better and 100% 0.2 logMAR or better.~~ At intermediate distance measured at 66 cm~~s~~, monocular outcomes were similar between the different IOLs. Mean monocular DCIVA was 0.27 ± 0.11 logMAR for the for the Eyhance[21], 0.27 ± 0.13 logMAR for the Isopure [19] and 0.28 ± 0.07 logMAR for the RayOne EMV in our study. The percentage of eyes with a monocular DCIVA of 0.3 logMAR or better was 83.3% with the Isopure and 91% with the RayOne EMV. ~~Binocularly, the DCIVA values were small differences within 1 line of visual acuity between the IOLs;~~M~~-m~~ean binocular DCIVA was 0.20 ± 0.11 logMAR for the Isopure [19], 0.15 ± 0.08 logMAR for the Eyhance [21] and 0.24 ±

Formatted: Strikethrough

0.09 logMAR for the ~~RayOne~~ RayOne EMV showing 59% of patients with binocular DCIVA of 0.2 logMAR or better. ~~Comparison of mean monocular logMAR DCIVA revealed very similar outcomes for the Eyhance (0.27 ± 0.11)[21], the Isopure (0.27 ± 0.13) [19] and the EMV (0.28 ± 0.07).~~ Randomized trials would be necessary to further evaluate if there are any ~~these~~ differences and conclude with certainty on the comparative performance of these lenses.

~~To further improve visual outcomes both at distance and intermediate with the RayOne EMV, it might be beneficial to target the dominant eye with emmetropia and the non-dominant eye with myopia. The emmetropic target in the dominant eye could result in an improvement of the uncorrected distance vision, and the myopic target in the non-dominant eye could result in an improvement of the uncorrected intermediate vision. This is the subject of an on-going study and results will be reported in the near future.~~

Patient satisfaction was high, with 96% of patients reporting satisfaction with their sight after surgery. Although the mean refractive error postoperatively was slightly myopic, the satisfaction level was high for all viewing distances, showing a good tolerance to small refractive errors. The spectacle independence results assessed in this study with the standardised Cat-Quest 9SF questionnaire further underline the good visual acuity results with RayOne EMV.

Some limitations of our study include the fact that defocus curve was only measured up to a defocus of +1.00 D; it would be beneficial to extend to a wider range of positive defocus to capture the full extended range of vision of the RayOne EMV. Further, preoperatively, eyes with corneal spherical aberration greater than 0.4 µm were excluded to ensure that the maximum spherical aberration postoperatively remained below the 0.6 µm threshold,[22, 23] with the aim of avoiding any potential impact on visual quality. Our approach leaned towards caution in the absence of prior published clinical studies on the RayOne EMV. Based on the findings from this study, future research may benefit from extending the inclusion criteria to

encompass patients with higher spherical aberration to evaluate the clinical threshold beyond which the lens advantages in extending the depth of focus become indiscernible. It is expected that ~~a majority of~~most eyes will be suitable for implantation with the RayOne EMV given that the average corneal spherical aberration for virgin eyes is approximately +0.27 ± 0.10 µm for a diameter of 6 mm~~.~~[24,25].

In conclusion, bilateral implantation of the enhanced monofocal RayOne EMV provided excellent binocular C~~U~~DVA and good DCIVA. ~~The UIVA showed that intermediate vision, with patients benefited~~ing from a small myopic refraction postoperatively. ~~–~~It was confirmed that the RayOne EMV induced positive spherical aberration resulting in an increased range of vision. The results of the quality of vision questionnaire demonstrated high levels of patient~~'s~~ satisfaction with 92% of patients reporting no difficultly with their vision in their everyday life.

Formatted: Strikethrough

WHAT WAS KNOWN

- Non-diffractive e~~xtended of focus~~nhanced monofocal IOLs provide patients a continuous range of good vision from distance to intermediate vision compared to monofocal IOLs.

WHAT THIS PAPER ADDS

- Bilateral implantation of the RayOne EMV ~~an~~ enhanced monofocal IOL, which induce~~s~~s controlled positive spherical aberration, ~~–~~ provide~~s~~e~~d~~ excellent binocular ~~un~~c~~e~~orrected distance and good intermediate visual acuity ~~and~~with high levels of patient satisfaction.

DISCLOSURES

On behalf of all authors, I do not declare any conflicts of interest regarding this publication. There was no financial support for this work. As corresponding author, I confirm that the manuscript has been read and approved for submission by all the nominated authors.

REFERENCES

1. de Vries NE, Nuijts RM. Multifocal intraocular lenses in cataract surgery: literature review of benefits and side effects. J Cataract Refract Surg. 2013;39:268-278.
2. Park ES, Ahn H, Han SU, Jun I, Seo KY, Kim EK, Kim Ti. Visual outcomes, spectacle independence, and patient satisfaction of pseudophakic mini-monovision using a new monofocal intraocular lens. Sci Rep. 2022; 12:26315-7.
3. Hovanesian JA, Jones M, Allen Q. The Vivity Extended Range of Vision IOL vs the PanOptix Trifocal, ReStor 2.5 Active Focus and ReStor 3.0 Multifocal Lenses: A Comparison of Patient Satisfaction, Visual Disturbances, and Spectacle Independence. Clin Ophthalmol. 2022; 16: 145-152.
4. Goldberg DG, Goldberg MD, Shah R, Meagher JN, Ailani H. Pseudophakic mini-monovision: high patient satisfaction, reduced spectacle dependence, and low cost. BMC Ophthalmol. 2018; 18: 293.
5. Salerno LC, Tiveron Jr, Alio JL. Multifocal intraocular lenses: types, outcomes, complications and how to solve them. Taiwan J Ophthalmol. 2017;7:179–184.
6. Monaco G, Gari M, Di Censo F, Poscia A, Ruggi G, Scialdone A. Visual performance after bilateral implantation of 2 new presbyopia-correcting intraocular lenses: Trifocal versus extended range of vision. J Cataract Refract Surg. 2017;43(6):737-747.

7. Ozulken K, Kiziltoprak H, Yuksel E, Mumcuoğlu T. A Comparative Evaluation of Diffractive Trifocal and New Refractive/Extended Depth of Focus Intraocular Lenses for Refractive Lens Exchange. Curr Eye Res. 2021 Jun;46(6):811-817.
8. Breyer DRH, Kaymak H, Ax T, Kretz FTA, Auffarth GU, Hagen PR. Multifocal intraocular lenses and extended depth of focus intraocular lenses. Asia Pac J Ophthalmol (Phila). 2017;6:339–349.
9. MacRay S, Holladay JT, Glasser A, Calogero D, Hilmantel G, Masket S, Stark W, Tarver ME, Nguyen T, Eydelman M. Special report: American Academy of Ophthalmology task force consensus statement for extended depth of focus intraocular lenses. Ophthalmology. 2017;124:139-141.
10. Rampat R, Gatinel D. Multifocal and Extended Depth-of-Focus Intraocular Lenses in 2020. Ophthalmology. 2021 Nov;128(11):164-185.
11. Rayner Brochure- RayOne EMV. *Accessed October 18, 2023.* ~~HYPERLINK "https://rayner.com/wp-content/uploads/2022/09/RAY04715_RayOne-EMV-Platform-Brochure-v7-Singles.pdf"~~ https://rayner.com/wp-content/uploads/2022/09/RAY04715_RayOne-EMV-Platform-Brochure-v7-Singles.pdf~~https://rayner.com/wp-content/uploads/2022/09/RAY04715_RayOne-EMV-Platform-Brochure-v7-Singles.pdf~~
12. Fernández J, Ribeiro FJ, Rodríguez-Vallejo M, Dupps WJ Jr, Werner L, Srinivasan S, Kohnen T. Standard for collecting and reporting outcomes of IOL-based refractive surgery: update for enhanced monofocal, EDOF, and multifocal IOLs. J Cataract Refract Surg. 2022 Nov 1;48(11):1235-1241.
13. Kang KH, Song MY, Kim KY, Hwang K-Y, Kwon Y-A, Koh K. Visual Performance and Optical Quality after Implantation of a New Generation Monofocal Intraocular Lens. Korean J Ophthalmol. 2021;35(2):112-119.

Formatted: Default Paragraph Font, Font: (Default) Arial, 11 pt

14. Bakaraju RC, Ehrmann K, Papas EB, Ho A. Depth-of-Focus and its Association with the Spherical Aberration Sign. A Ray-Tracing Analysis. J Optom. 2010;3(1):51–9.
15. Schmid R, ·Borkenstein AF. Analysis of higer order aberrations in recently developed wavefront-shaped IOLs. Graefes Arch Clin Exp Ophthalmol. 2022; 260(2): 609-620.
16. Schmid R, Fuchs C, Luedtke H, Borkenstein A. Eur J Ophthalmol. Depth of focus of four novel extended range of vision intraocular lenses. Eur J Ophthalmol. 2023 Jan;33(1):257-261.
17. Alarcon A, Canovas C, Koopman B, Pande M, Koch D, Piers P. Optical bench evaluation of the effect of pupil size in new generation monofocal intraocular lenses. BMC Ophthalmology. 2023; 23 (112):1-8
18. Auffarth G, Gerl M, Tsai L, Janakiraman P, Jackson B, Alarcon A, Dick, HB. Clinical evaluation of a new monofocal IOL with enhanced intermediate function in patients with cataract. J Cataract Refract Surg. 2021 47(2): 184-191.
19. Stodulka P, Slovak M. Visual Performance of a Polynomial Extended Depth of Focus Intraocular Lens. Open Journal of Ophthalmology, 2021, 11, 214-228.
20. Hyuck Lee J, Moon SY, Chung HS, Park SO. Clinical outcomes of a monofocal intraocular lens with enhanced intermediate function compared with an extended depth-of-focus intraocular lens. J Cataract Refract Surg. 2022 48(1):61-66.
21. Mencucci R, Cennamo M, Venturi D, Vignapiano R, Favuzza E. Visual outcome, optical quality, and patient satisfaction with a new monofocal IOL, enhanced for intermediate vision: preliminary results. J Cataract Refract Surg. 2020; 46(3): 378-387.
22. Rocha KM, Vabre L, Château N, Krueger RR. Expanding depth of focus by modifying higher-order aberrations induced by an adaptive optics visual simulator. J Cataract Refract Surg. 2009; 35: 1885-1892

23. Reinstein DZ, Archer TA, Couch D, Schroeder E, Wottke M. A new night vision disturbances parameter and contrast sensitivity as indicators of success in wavefront-guided enhancement. J Refract Surg. 2005 Sep-Oct;21(5):S535-40.

24. Beiko G.H.H., Haigis W., Steinmueller A. Distribution of the corneal spherical aberration in a comprehensive ophthalmology practice, and can keratometry be predictive of the value of the corneal spherical aberration? J Cataract Refract Surg. 2007;33(5):848–858.

25. Holladay J.T., Piers P.A., Koranyi G., van der Mooren M., Norrby S. A new intraocular lens design to reduce spherical aberration of pseudophakic eyes. J Refract Surg. 2002;1(8):683–691.

TABLE LEGENDS

Table 1: Mean preoperative demographics. SEQ: Spherical Equivalent (D)

Table 2: Mean monocular and binocular Uncorrected Distance Visual Acuity (UDVA), Corrected Distance Visual Acuity (CDVA), Uncorrected Intermediate Visual Acuity (UIVA) and Distance Corrected Intermediate Visual Acuity (DCIVA) preoperatively, at Month-1 and Month-3 postoperatively.

Supplemental Table

Supplemental Table 1: Mean preoperative and postoperative ocular (whole eye), corneal and internal eye spherical aberrations measured with the KR-1W for the 4 mm and 6 mm pupil diameters (in μm)

FIGURE LEGENDS

Figure 1: Standard graphs for reporting refractive outcomes after IOL implantation (25 eyes, 3 months postoperatively)

A: Distribution of postoperative Spherical Equivalent (SEQ) refraction. B: Distribution of postoperative refractive cylinder C: Change in Snellen lines between postoperative CDVA and postoperative UDVA.

Figure 2: A: Cumulative distribution of monocular uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA). B: Cumulative distribution of monocular uncorrected intermediate visual acuity (UIVA) and distance corrected intermediate visual acuity (DCIVA). C: Cumulative distribution of binocular UDVA and CDVA.D: Cumulative distribution of binocular UIVA and DCIVA

Figure 3: Photopic monocular and binocular defocus curves (measured with the best distance correction in place)

Figure 4: Results of the CatQuest-9SF questionnaire at the Month-3 postoperative visit.

A: Do you find that your sight at present causes you difficulty in your everyday life?

B: Are you satisfied or dissatisfied with your sight at present?

Do you have difficulties with the following activities because of your sight?

C1: Reading text in newspapers

C2: Recognizing faces of people you meet

C3: Seeing the process of goods when shopping

C4: Seeing to walk on uneven surfaces

C5: Seeing to do handicrafts, woodwork

C6: Reading subtitles on TV

C7: Seeing to engage in an activity/hobby that you are interested in

TITLE

Visual and Refractive Outcomes after Bilateral Implantation of an Enhanced Monofocal IOL: a Prospective study.

ABSTRACT

Purpose: To evaluate visual and refractive outcomes, as well as patient satisfaction after bilateral implantation of an enhanced monofocal intraocular lens (IOL) with emmetropia as a target refraction.

Setting: San Carlos Hospital, Madrid, Spain.

Design: Prospective, monocentric, non-comparative study.

Methods: Adults 21 years or older suitable for cataract surgery and with corneal astigmatism < 1.50D were bilaterally implanted with the RayOne EMV IOL and followed up for 3-months. Outcomes measures included refraction, monocular and binocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), distance corrected intermediate visual acuity (DCIVA), and defocus curve, aberrometry, and satisfaction. Visual symptoms were assessed using the CatQuest-9SF questionnaire.

Results: 50 eyes of 25 patients were included. At Month-3, the mean manifest spherical equivalent was -0.39 ± 0.28 D, with all eyes within 1.00 D. Binocularly, uncorrected, at distance, 68% of patients could read ≤ 0.0 logMAR and 95% ≤ 0.2 logMAR; at intermediate 59% of patients could read ≤0.1 and 100% ≤ 0.2 logMAR. Mean monocular CDVA was -0.03 ± 0.06 logMAR and mean monocular DCIVA was 0.28 ± 0.07 logMAR. Binocular defocus curve demonstrated a visual acuity ≤ 0.2 logMAR over a 2 D range from +1.00 D to -1.25 D. Satisfaction was good in 96% of patients.

Conclusion: Bilateral implantation of an enhanced monofocal IOL with emmetropia as a target provided excellent binocular CDVA and good DCIVA, with a high level of satisfaction..

INTRODUCTION

The standard of care in cataract surgery is changing with the continuous development of presbyopia-correcting IOLs as well as the increasing patients' demand for restoration of functional vision at all distances. Increased spectacle independence has resulted in an increase in quality of life after surgery[1] as well as increased patient satisfaction.[2-4]

Monofocal IOLs are commonly implanted and provide good distance vision and minimal visual disturbances; however, monofocal IOLs are not designed to offer spectacle independence at near or intermediate. On the other hand, multifocal IOLs have been shown to provide acceptable visual acuity from distance to near, however, their main disadvantages remain a loss in contrast sensitivity and increased visual disturbances such as halos and glare.[5]

Extended depth of focus (EDoF) IOLs have been developed with the aim of providing patients with a continuous range of good vision from distance to intermediate, while limiting dysphotopsia.[6, 7] Instead of splitting the focusing light into separate focal points, these lenses create a single elongated focal point to enhance the depth of focus, improving intermediate vision without compromising distance vision.[8, 9] However, the performance of diffractive EDoF IOLs still has limitations, including reduced quality of vision.

Non-diffractive enhanced monofocal IOLs share a similar objective of primarily optimising distance vision while extending the range of vision toward the intermediate range, but without compromising quality of vision and binocular distance vision. Non-diffractive elongation of the depth-of-focus, can be achieved through various methods such as small apertures, wavefront shaping technologies, or manipulations of spherical aberrations.[10]

Amongst these, the RayOne EMV RAO200E lens (Rayner Intraocular Lenses Limited, Worthing, UK) is a non-diffractive, monofocal aspheric lens, designed to extend the range of vision by inducing a controlled amount of positive spherical aberrations, unlike other

technologies using negative spherical aberration. The aim of this study was to evaluate refractive and visual outcomes as well as patient satisfaction after bilateral implantation of the RayOne EMV RAO200E.

METHODS

This prospective, single centre, observational, non-comparative study was performed at San Carlos Hospital, in Madrid Spain. The study was reviewed and approved by the hospital's Ethics Committee (Reference 21/664-O_P). Written informed consent was obtained from all patients preoperatively, after they were fully informed about the purpose of the study. The study followed the tenets of the Declaration of Helsinki.

Patients included in the study were men and women aged 21 years or older who presented with bilateral cataract and suitable for cataract surgery with bilateral implantation of the RayOne EMV IOL. Other inclusion criteria were: preoperative corneal astigmatism < 1.50D, potential for best-corrected distance visual acuity (CDVA) of 0.18 logMAR or better postoperatively, and calculated IOL power in the range of +10.0 D to +30.0 D. Subjects were excluded from participation if they suffered from other co-morbidity such as other medical or ocular conditions that could affect the outcome. Eyes with preoperative corneal positive spherical aberration greater than 0.40 µm for a 6-mm pupil were excluded.

Patients attended a preoperative visit, and three postoperative visits: 1 to 2 days after surgery (Day-1), 30 to 60 days after surgery (Month-1), and 100 to 120 days after surgery (Month-3).

Intraocular lens

The CE-marked RayOne EMV RAO200E lens (Rayner Intraocular Lenses Limited, Worthing, UK) is made of Rayacryl hydrophilic acrylic; it is a non-diffractive enhanced monofocal aspheric IOL. The centre of the optics induces controlled positive spherical aberration (maximum 0.15 µm across the 6-mm optic) to spread light along the visual axis and elongate

the focal range from far into intermediate and the blended edge reduces longitudinal spherical aberration to maintain visual acuity and contrast sensitivity in mesopic conditions. It has a refractive index of 1.46 and an Abbe number of 56.[11]

The IOL is fully preloaded in the RayOne injector in the full power range (+10.0 D to +30.0 D in 0.5 D increments) and allows implantation through a 2.2 mm incision. The injector features a syringe-shaped design to allow for a one-handed IOL placement technique.

Surgical Procedure

The surgery was performed as per the surgeon preferred micro-incision surgical technique under topical anesthesia, using standard phacoemulsification and a 2.2 mm incision.

Biometry was measured using the IOL master 700 (Carl Zeiss Meditec, Jena, Germany). IOL power was calculated using the Barrett Universal II Formula (lens factor 1.67; design factor 3.5) and the manufacturer suggested A-constant of 118.6. The target refraction was emmetropia for both eyes; the IOL power was selected as the IOL power resulting in the smallest postoperative myopic refraction (i.e., the closest myopic refraction to zero), rather than resulting in the refraction closest to zero.

Postoperative medication was prescribed according to hospital protocol, including topical antibiotics and steroids.

Preoperative and Postoperative Assessments

Visual acuity was measured using ETDRS charts, with 100% contrast, under photopic conditions and reported in logMAR. Uncorrected distance visual acuity (UDVA) and CDVA were measured monocularly and binocularly at 4 meters. Uncorrected intermediate visual acuity (UIVA) and distance corrected intermediate visual acuity (DCIVA) were measured monocularly and binocularly at 66 cm. DCIVA was measured with the distance manifest

refraction in place as per recommended published standards.[12] Visual acuities were measured at 1-month and 3-month visits.

Defocus curve was performed with the manifest refraction in place, monocularly (at the 1-month visit) and binocularly (at the 3-month visit) under photopic conditions (85 cd/m^2), with defocus values between +1.00 D to -2.50 D in 0.50 D steps.

Pupillometry was measured using the KR-1W wavefront analyser (Topcon, Tokyo, Japan).

Preoperatively, corneal aberrations were measured with the Pentacam (Oculus GmbH, Wetzlar, Germany) for the 6 mm pupil diameter. Postoperatively, corneal and ocular aberrations were measured with the Hartmann-Shack KR-1W wavefront analyser.

Patient satisfaction and spectacle independence were measured using the validated CatQuest-9SF questionnaire.

Aberrometry and questionnaires were performed at 3-month visit.

Adverse events were recorded at all visits.

Statistical Analysis

Sample size was calculated using published results related to UIVA by Kang et al.[13] Given an alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test, it was calculated that 25 subjects were required to achieve a statistically significant difference greater than or equal to 0.06 logMAR units. The standard deviation was assumed to be 0.1. It had been anticipated a drop-out rate of 10%.

Data analysis was performed with the SPSS software for Windows, version 26.0 (IBM, Armonk, NY, USA). The study data were analysed using descriptive statistics including mean and standard deviation (SD) for each parameter. For each study metric, normality was analysed using the Shapiro-Wilk test. When parametric analysis was possible, t test for paired data was

used to compare results between consecutive visits. When parametric analysis was not possible, the Wilcoxon test was used to compare parameters across visits. For all statistical tests, a p-value of less than 0.05 was considered to be statistically significant.

Only the right eye of each patient was included in the analysis of refraction and monocular visual acuity.

RESULTS

A total of 25 patients (50 eyes) were included and bilaterally implanted with the EMV IOL. All patients completed the 3-Month follow-up. Mean preoperative characteristics are described in Table 1.

Refractive Results

Postoperative mean spherical equivalent (SEQ) was -0.47 ± 0.39 D (-1.75 D to 0.00 D) at Month-1 and -0.39 ± 0.28 D (-1.00 D to 0.25 D) at Month-3. Figure 1A shows the distribution of the SEQ at Month-3: 87.0% of eyes were within ±0.50 D and 100% of eyes within ±1.00 D of emmetropia.

Postoperative astigmatism was -0.50 ± 0.44 D (-1.50 D to 0.00 D) at Month-1 and -0.52 ± 0.44 D (-1.25 D to 0.00 D) at Month-3. Figure 1B shows the distribution of refractive astigmatism at Month-3: 60.9% of eyes were within ±0.50 D and 87.0% of eyes within ±1.00 D of target.

Visual Acuity Results

Mean visual acuity values are shown in Table 2.

All eyes had a monocular CDVA of 0.06 logMAR or better, except one eye diagnosed with macular edema at the 1-month visit and persisting at the 3-month visit with a CDVA of 0.3 logMAR.

Figure 1C shows the distribution of the difference between postoperative monocular UDVA and postoperative monocular CDVA; UDVA was within 1 line of CDVA for 92% of eyes.

Mean monocular UDVA (at 4 m) was 0.06 ± 0.11 logMAR at Month-3. As shown on Figure 2A, at Month-3, UDVA was 0.0 logMAR or better in 58% of eyes, 0.1 logMAR or better in 88% of eyes, and 0.2 logMAR or better in 96% of eyes. Binocularly (Figure 2C), UDVA was 0.1 logMAR or better in 95% of patients, and 0.2 logMAR or better in all patients.

At Month-3, mean monocular UIVA (at 66 cm) was 0.19 ± 0.09 logMAR; UIVA was 0.1 logMAR or better in 35% of eyes, 0.2 logMAR or better in 78%, and 0.3 logMAR or better in 96% of eyes (Figure 2B). Binocularly (Figure 2D), UIVA was 0.1 logMAR or better in 59% of patients and 0.2 logMAR or better in all patients.

At Month-3, mean monocular DCIVA was 0.28 ± 0.07 logMAR. As shown on Figure 2B, DCIVA was 0.1 logMAR or better in 4% of eyes, 0.2 logMAR or better in 39%, and 0.3 logMAR or better in 91% of eyes. Binocularly (Figure 2D), DCIVA was 0.1 logMAR or better in 23% of patients, 0.2 logMAR or better in 59% of patients, and 0.3 logMAR or better in 86% of patients.

Defocus Curve

The distance corrected monocular and binocular defocus curves (Figure 3) showed a peak at defocus 0.00 D (4 m) and as expected, a gradual continuous reduction in visual acuity with the increase in negative defocus (near vision). For a defocus of -1.50 D (equivalent to a 66 cm viewing distance), mean visual acuity was 0.36 ± 0.12 logMAR monocularly and 0.24 ± 0.09 binocularly.

Questionnaires

Figure 4 shows the results of the CatQuest-9SF questionnaire obtained at Month-3. Most patients (92%) reported that their vision did not cause any difficulty in their everyday life. In

terms of satisfaction, 58% of patients reported being very satisfied with their present vision and 38% of patients reported being fairly satisfied. In terms of difficulties with everyday tasks, most patients (between 80% and 96%) reported no difficulty with recognizing faces, seeing prices of goods when shopping, seeing to walk on uneven ground, seeing to do needlework and handicraft, reading text on television, and seeing to carry out a preferred hobby. For reading text in newspaper, 58% of patients reported no difficulty, 37% reported some difficulty, and 4% reporting great difficulties. No patient reported being very dissatisfied or having very great difficulties for any questions.

Corneal and Ocular Aberrations

Mean preoperative and 3-month postoperative corneal and ocular spherical aberrations are presented in Supplemental Table 1. There was no statistically significant change in corneal spherical aberrations after surgery for the 4 mm pupil ($p=0.105$) and 6 mm pupil ($p=0.057$). There was a statistically significant increase in ocular spherical aberrations ($p<0.001$) for both the 4-mm pupil (from 0.04 ± 0.11 µm to 0.10 ± 0.04 µm) and the 6-mm pupil (from 0.07 ± 0.40 µm to 0.38 ± 0.17 µm) induced by the RayOne EMV IOL.

Adverse Events

Three non-serious adverse events were identified, all cystoid macular oedema. One was experienced monocularly, and the other two occurred in the same patient. Two adverse events resolved before the 1-month visit. In the third eye, despite apparent resolution on OCT, loss of CDVA persisted at month-1 and month-3 (CDVA of 0.30 logMAR). A subsequent visit showed improvement in CDVA, suggesting unresolved CME at month-3. Consequently, this eye was excluded from the visual and refractive outcomes analysis.

There were no intraoperative adverse events.

DISCUSSION

The RayOne EMV is the only enhanced monofocal IOL on the market using positive spherical aberration rather than negative spherical aberration to increase depth of focus. Regarding presbyopic-correction strategies using induced aberrations for increased depth of focus, Bakaraju et al.[14] reported that both positive and negative spherical aberration have equal potential. The IOL was designed so that the induced positive spherical aberration complements the natural positive spherical aberration of the human cornea. An equivalent negative spherical aberration IOL needs to first negate the positive spherical aberration of the cornea, then add even more negative spherical aberration to induce any required depth of focus improvements. The total spherical aberration used on the RayOne EMV is therefore designed to be significantly less than for equivalent negative spherical aberration extended depth IOLs. Using optical bench analysis, Schmid et al.[15] confirmed a positive increase in spherical aberration, as per the manufacturer's claim. Our clinical study corroborated that the RayOne EMV IOL induces positive spherical aberration in implanted eyes. Corneal aberrations remained unchanged after surgery, however ocular spherical aberrations positively increased postoperatively, averaging 0.38 ± 0.17 µm (range: 0.02 µm to 0.72 µm) for the 6-mm pupil.

The increase in spherical aberration was also significant for the 4-mm pupil, increasing from 0.04 ± 0.11 µm before surgery to 0.10 ± 0.04 µm after surgery. This is important as a 4 mm pupil diameter closely aligns with the average pupil size of 3.6 mm measured under photopic conditions in our study. This supports the finding that the improvement in intermediate vision is due to the increased depth of field resulting from the increase in spherical aberration.

At the time of writing, there are only published studies assessing the optical quality of the RayOne EMV using optical bench evaluation. This is the first in humans' study reporting the visual and refractive outcomes of patients implanted with the RayOne EMV. Schmid et al.[16]

compared 4 enhanced monofocal IOLs in an optical bench study and concluded that for a small aperture, the peak modulation transfer function was best for the Eyhance IOL (Johnson & Johnson Vision, Santa Ana, USA) and RayOne EMV indicating excellent distance quality of vision. Alarcon et al.[17] also performed optical bench testing to evaluate the distance image quality of three enhanced monofocal IOLs including the RayOne EMV. The simulated visual acuity demonstrated that the RayOne EMV provided as good distance vision as that of a standard monofocal; both papers are in good agreement with the clinical findings in our study where mean CDVA was excellent and slightly better than 20/20 (-0.03 ± 0.06 logMAR).

In the absence of previously published clinical data on the RayOne EMV, we compared our results with published literature on other non-diffractive enhanced monofocal IOLs, also offering an increased range of vision,[18] including the Tecnis Eyhance ICB00 (Johnson & Johnson Vision, Santa Ana, USA), and the ISOPURE 1.2.3 (PhysIOL S.A, Liege, Belgium). Given that the spherical aberration of any optical system is dependent on the height of incoming light rays with respect to the optic axis, and therefore on the diameter of the entrance pupil of the system, it is important to understand the strategies used by the manufacturers to increase the depth of focus with these IOLs. It should be considered that positive spherical aberration induces an extra positive power in the lens periphery compared to its central zone. Conversely, negative spherical aberration leads to greater power in the central zone.

In our study, refractive accuracy was excellent with 87% of eyes within ±0.50 D and all eyes within ±1.00 D of target. These results are consistent with published data on other enhanced monofocal IOLs. In our study, most eyes were slightly myopic postoperatively (mean postoperative SEQ: -0.36 ± 0.28 D) aligning with the preference for a small myopic postoperative target over a hypermetropic one while targeting emmetropia in all eyes. The small postoperative myopic spherical equivalent did not greatly affect uncorrected visual acuity; mean binocular uncorrected distance vision at 3-months after surgery was good (0.01 ±

0.08 logMAR) with 68% of patients reaching 0.0 logMAR or better, and 95% reaching 0.1 logMAR or better.

Binocular UDVA in our study (0.01 ± 0.08 logMAR) was comparable to previously reported for other IOLs: 0.03 ± 0.12 logMAR for the Eyhance[18] and -0.02 ± 0.13 logMAR for the Isopure [19].

At intermediate distance measured at 66 cm, monocular outcomes were similar between the different IOLs. Mean monocular DCIVA was 0.27 ± 0.11 logMAR for the for the Eyhance[21], 0.27 ± 0.13 logMAR for the Isopure [19] and 0.28 ± 0.07 logMAR for the RayOne EMV in our study. The percentage of eyes with a monocular DCIVA of 0.3 logMAR or better was 83.3% with the Isopure and 91% with the RayOne EMV. Mean binocular DCIVA was 0.20 ± 0.11 logMAR for the Isopure [19], 0.15 ± 0.08 logMAR for the Eyhance [21] and 0.24 ± 0.09 logMAR for the RayOne EMV showing 59% of patients with binocular DCIVA of 0.2 logMAR or better. Randomized trials would be necessary to further evaluate if there are any differences and conclude with certainty on the comparative performance of these lenses.

Patient satisfaction was high, with 96% of patients reporting satisfaction with their sight after surgery. Although the mean refractive error postoperatively was slightly myopic, the satisfaction level was high for all viewing distances, showing a good tolerance to small refractive errors. The spectacle independence results assessed in this study with the standardised Cat-Quest 9SF questionnaire further underline the good visual acuity results with RayOne EMV.

Some limitations of our study include the fact that defocus curve was only measured up to a defocus of +1.00 D; it would be beneficial to extend to a wider range of positive defocus to capture the full extended range of vision of the RayOne EMV. Further, preoperatively, eyes with corneal spherical aberration greater than 0.4 µm were excluded to ensure that the

maximum spherical aberration postoperatively remained below the 0.6 μm threshold,[22, 23] with the aim of avoiding any potential impact on visual quality. Our approach leaned towards caution in the absence of prior published clinical studies on the RayOne EMV. Based on the findings from this study, future research may benefit from extending the inclusion criteria to encompass patients with higher spherical aberration to evaluate the clinical threshold beyond which the lens advantages in extending the depth of focus become indiscernible. It is expected that most eyes will be suitable for implantation with the RayOne EMV given that the average corneal spherical aberration for virgin eyes is approximately +0.27 ± 0.10 μm for a diameter of 6 mm[24,25].

In conclusion, bilateral implantation of the enhanced monofocal RayOne EMV provided excellent binocular CDVA and good DCIVA. It was confirmed that the RayOne EMV induced positive spherical aberration resulting in an increased range of vision. The results of the quality of vision questionnaire demonstrated high levels of patient satisfaction with 92% of patients reporting no difficultly with their vision in their everyday life.

WHAT WAS KNOWN

- Non-diffractive enhanced monofocal IOLs provide patients a continuous range of good vision from distance to intermediate vision compared to monofocal IOLs.

WHAT THIS PAPER ADDS

- Bilateral implantation of the RayOne EMV enhanced monofocal IOL, which induces controlled positive spherical aberration, provides excellent binocular corrected distance and good intermediate visual acuity with high levels of patient satisfaction.

DISCLOSURES

On behalf of all authors, I do not declare any conflicts of interest regarding this publication. There was no financial support for this work. As corresponding author, I confirm that the manuscript has been read and approved for submission by all the nominated authors.

REFERENCES

1. de Vries NE, Nuijts RM. Multifocal intraocular lenses in cataract surgery: literature review of benefits and side effects. J Cataract Refract Surg. 2013;39:268-278.
2. Park ES, Ahn H, Han SU, Jun I, Seo KY, Kim EK, Kim Ti. Visual outcomes, spectacle independence, and patient satisfaction of pseudophakic mini-monovision using a new monofocal intraocular lens. Sci Rep. 2022; 12:26315-7.
3. Hovanesian JA, Jones M, Allen Q. The Vivity Extended Range of Vision IOL vs the PanOptix Trifocal, ReStor 2.5 Active Focus and ReStor 3.0 Multifocal Lenses: A Comparison of Patient Satisfaction, Visual Disturbances, and Spectacle Independence. Clin Ophthalmol. 2022; 16: 145-152.
4. Goldberg DG, Goldberg MD, Shah R, Meagher JN, Ailani H. Pseudophakic mini-monovision: high patient satisfaction, reduced spectacle dependence, and low cost. BMC Ophthalmol. 2018; 18: 293.
5. Salerno LC, Tiveron Jr, Alio JL. Multifocal intraocular lenses: types, outcomes, complications and how to solve them. Taiwan J Ophthalmol. 2017;7:179–184.
6. Monaco G, Gari M, Di Censo F, Poscia A, Ruggi G, Scialdone A. Visual performance after bilateral implantation of 2 new presbyopia-correcting intraocular lenses: Trifocal versus extended range of vision. J Cataract Refract Surg. 2017;43(6):737-747.

7. Ozulken K, Kiziltoprak H, Yuksel E, Mumcuoğlu T. A Comparative Evaluation of Diffractive Trifocal and New Refractive/Extended Depth of Focus Intraocular Lenses for Refractive Lens Exchange. Curr Eye Res. 2021 Jun;46(6):811-817.
8. Breyer DRH, Kaymak H, Ax T, Kretz FTA, Auffarth GU, Hagen PR. Multifocal intraocular lenses and extended depth of focus intraocular lenses. Asia Pac J Ophthalmol (Phila). 2017;6:339–349.
9. MacRay S, Holladay JT, Glasser A, Calogero D, Hilmantel G, Masket S, Stark W, Tarver ME, Nguyen T, Eydelman M. Special report: American Academy of Ophthalmology task force consensus statement for extended depth of focus intraocular lenses. Ophthalmology. 2017;124:139-141.
10. Rampat R, Gatinel D. Multifocal and Extended Depth-of-Focus Intraocular Lenses in 2020. Ophthalmology. 2021 Nov;128(11):164-185.
11. Rayner Brochure- RayOne EMV. *Accessed October 18, 2023.* https://rayner.com/wp-content/uploads/2022/09/RAY04715_RayOne-EMV-Platform-Brochure-v7-Singles.pdf
12. Fernández J, Ribeiro FJ, Rodríguez-Vallejo M, Dupps WJ Jr, Werner L, Srinivasan S, Kohnen T. Standard for collecting and reporting outcomes of IOL-based refractive surgery: update for enhanced monofocal, EDOF, and multifocal IOLs. J Cataract Refract Surg. 2022 Nov 1;48(11):1235-1241.
13. Kang KH, Song MY, Kim KY, Hwang K-Y, Kwon Y-A, Koh K. Visual Performance and Optical Quality after Implantation of a New Generation Monofocal Intraocular Lens. Korean J Ophthalmol. 2021;35(2):112-119.
14. Bakaraju RC, Ehrmann K, Papas EB, Ho A. Depth-of-Focus and its Association with the Spherical Aberration Sign. A Ray-Tracing Analysis. J Optom. 2010;3(1):51–9.

15. Schmid R, ·Borkenstein AF. Analysis of higer order aberrations in recently developed wavefront-shaped IOLs. Graefes Arch Clin Exp Ophthalmol. 2022; 260(2): 609-620.
16. Schmid R, Fuchs C, Luedtke H, Borkenstein A. Eur J Ophthalmol. Depth of focus of four novel extended range of vision intraocular lenses. Eur J Ophthalmol. 2023 Jan;33(1):257-261.
17. Alarcon A, Canovas C, Koopman B, Pande M, Koch D, Piers P. Optical bench evaluation of the effect of pupil size in new generation monofocal intraocular lenses. BMC Ophthalmology. 2023; 23 (112):1-8
18. Auffarth G, Gerl M, Tsai L, Janakiraman P, Jackson B, Alarcon A, Dick, HB. Clinical evaluation of a new monofocal IOL with enhanced intermediate function in patients with cataract. J Cataract Refract Surg. 2021 47(2): 184-191.
19. Stodulka P, Slovak M. Visual Performance of a Polynomial Extended Depth of Focus Intraocular Lens. Open Journal of Ophthalmology, 2021, 11, 214-228.
20. Hyuck Lee J, Moon SY, Chung HS, Park SO. Clinical outcomes of a monofocal intraocular lens with enhanced intermediate function compared with an extended depth-of-focus intraocular lens. J Cataract Refract Surg. 2022 48(1):61-66.
21. Mencucci R, Cennamo M, Venturi D, Vignapiano R, Favuzza E. Visual outcome, optical quality, and patient satisfaction with a new monofocal IOL, enhanced for intermediate vision: preliminary results. J Cataract Refract Surg. 2020; 46(3): 378-387.
22. Rocha KM, Vabre L, Château N, Krueger RR. Expanding depth of focus by modifying higher-order aberrations induced by an adaptive optics visual simulator. J Cataract Refract Surg. 2009; 35: 1885-1892

23. Reinstein DZ, Archer TA, Couch D, Schroeder E, Wottke M. A new night vision disturbances parameter and contrast sensitivity as indicators of success in wavefront-guided enhancement. J Refract Surg. 2005 Sep-Oct;21(5):S535-40.

24. Beiko G.H.H., Haigis W., Steinmueller A. Distribution of the corneal spherical aberration in a comprehensive ophthalmology practice, and can keratometry be predictive of the value of the corneal spherical aberration? J Cataract Refract Surg. 2007;33(5):848–858.

25. Holladay J.T., Piers P.A., Koranyi G., van der Mooren M., Norrby S. A new intraocular lens design to reduce spherical aberration of pseudophakic eyes. J Refract Surg. 2002;1(8):683–691.

TABLE LEGENDS

Table 1: Mean preoperative demographics. SEQ: Spherical Equivalent (D)

Table 2: Mean monocular and binocular Uncorrected Distance Visual Acuity (UDVA), Corrected Distance Visual Acuity (CDVA), Uncorrected Intermediate Visual Acuity (UIVA) and Distance Corrected Intermediate Visual Acuity (DCIVA) preoperatively, at Month-1 and Month-3 postoperatively.

Supplemental Table

Supplemental Table 1: Mean preoperative and postoperative ocular (whole eye), corneal and internal eye spherical aberrations measured with the KR-1W for the 4 mm and 6 mm pupil diameters (in μm)

FIGURE LEGENDS

Figure 1: Standard graphs for reporting refractive outcomes after IOL implantation (25 eyes, 3 months postoperatively)

A: Distribution of postoperative Spherical Equivalent (SEQ) refraction. B: Distribution of postoperative refractive cylinder C: Change in Snellen lines between postoperative CDVA and postoperative UDVA.

Figure 2: A: Cumulative distribution of monocular uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA). B: Cumulative distribution of monocular uncorrected intermediate visual acuity (UIVA) and distance corrected intermediate visual acuity (DCIVA). C: Cumulative distribution of binocular UDVA and CDVA.D: Cumulative distribution of binocular UIVA and DCIVA

Figure 3: Photopic monocular and binocular defocus curves (measured with the best distance correction in place)

Figure 4: Results of the CatQuest-9SF questionnaire at the Month-3 postoperative visit.

A: Do you find that your sight at present causes you difficulty in your everyday life?

B: Are you satisfied or dissatisfied with your sight at present?

Do you have difficulties with the following activities because of your sight?

C1: Reading text in newspapers

C2: Recognizing faces of people you meet

C3: Seeing the process of goods when shopping

C4: Seeing to walk on uneven surfaces

C5: Seeing to do handicrafts, woodwork

C6: Reading subtitles on TV

C7: Seeing to engage in an activity/hobby that you are interested in

Editors:

William J. Dupps Jr, MD, PhD

Thomas Kohnen, MD, PhD, FEBO

Madrid, 21 of June 2023

Dear Editors,

Please find attached our manuscript entitled "Visual and Refractive Outcomes after Bilateral Implantation of an Enhanced Monofocal IOL: a Prospective study", as a research paper for consideration by Journal of Cataract & Refractive Surgery.

The submitted work deals with evaluated visual and refractive outcomes, as well as patient satisfaction after bilateral implantation of an enhanced monofocal intraocular lens, RayOne EMV, with emmetropia as a target refraction. We trust that our report is of great interest to the readers of your journal.

We confirm that this manuscript is original and has not been published elsewhere, and is not currently under review for publication elsewhere.

None of the authors have conflict of interest associated with this manuscript. As Corresponding Author, I confirm that the manuscript has been read and approved for submission by all the authors, who have contributed significantly.

Thank you for your consideration of this manuscript.

Sincerely,

Celia Villanueva, MSc

Department of Ophthalmology

Clinico San Carlos Hospital

celia.villanueva.hcsc@gmail.com

SYNOPSIS

Bilateral implantation of the enhanced monofocal RayOne EMV IOL with emmetropia as a target provided good unaided distance and intermediate vision and a high level of satisfaction.

TITLE PAGE

Title:

Visual and Refractive Outcomes after Bilateral Implantation of an Enhanced Monofocal IOL: a Prospective study.

Short title:

Visual Outcomes after Enhanced Monofocal IOL implant.

Authors names and affiliations

Javier García-Bella, MD, PhD[1]

Bárbara Burgos-Blasco, MD, PhD[1]

Beatriz Vidal-Villegas, MD, PhD[1]

Nuria Garzón, OD, MSc, PhD[2]

Celia Villanueva, GOO, MSc[1,2]

Julián García-Feijoo, MD, PhD[1]

1. Department of Ophthalmology. Clinico San Carlos Hospital, Madrid, Spain.
2. Faculty of Optics and Optometry. Complutense University Of Madrid, Madrid, Spain.

Corresponding author

Celia Villanueva.

Department of Ophthalmology, Hospital Clinico San Carlos

Address: C/ Profesor Martín Lagos S/N, 28040, Madrid, Spain

Mailing address: celia.villanueva.hcsc@gmail.com

Disclosures

On behalf of all authors, I do not declare any conflicts of interest regarding this publication. There was no financial support for this work. As corresponding author, I confirm that the manuscript has been read and approved for submission by all the nominated authors.

Figure 1



Figure 2



Figure 3



Figure 4

Click here to access/download;Figure;Figure 4.tif



Table 1: Mean preoperative demographics. SEQ: Spherical Equivalent 9D)

		Mean ± SD (Range)
Age (years)		69.2 ± 8.1 (50 to 81)
Gender		Female: 72%; Male: 28%
SEQ (D)		-0.50 ± 2.94 (-8.50 to +3.50)
Mean keratometry (D)		43.61 ± 1.53 (41.08 to 47.10)
Corneal astigmatism (D)		0.63 ± 0.35 (0.00 to 1.36)
Refractive astigmatism (D)		-0.81 ± 0.54 (0.25 to 2.25)
Axial length (mm)		23.41 ± 1.53 (22.34 to 25.12)
Anterior chamber depth (mm)		3.11 ± 0.30 (2.58 to 3.90)
Pupil diameter (mm)	Photopic	3.6 ± 0.7 (2.3 to 4.6)
	Mesopic	5.4 ± 1.0 (2.8 to 6.6)
Corneal spherical aberration (Z_4^0) for the 6mm pupil (µm)		0.33 ± 0.06 (0.20 to 0.39)
IOL power (D)		21.38 ± 2.02 (16.00 to 25.50)

Table 2: Mean monocular and binocular Uncorrected Distance Visual Acuity (UDVA), Corrected Distance Visual Acuity (CDVA), Uncorrected Intermediate Visual Acuity (UIVA) and Distance Corrected Intermediate Visual Acuity (DCIVA) preoperatively, at Month-1 and Month-3 postoperatively.

LogMAR		**Preoperatively**	**Month-1**	**Month-3**	**p-value (1M vs 3M)**
UDVA	monocular	0.59 ± 0.23 (0.00 to 0.60)	0.13±0.20 (-0.10 to 0.74)	0.06 ± 0.11 (-0.10 to 0.42)	0.047
UDVA	binocular	0.38 ± 0.22 (0.10 to 0.94)	0.06 ± 0.16 (-0.08 to 0.72)	0.01 ± 0.08 (-0.08 to 0.20)	0.203
CDVA	monocular	0.20 ± 0.16 (0.02 to 0.66)	-0.01 ± 0.07 (-0.20 to 0.16)	-0.03 ± 0.06 (-0.20 to 0.06)	0.137
CDVA	binocular	0.09 ± 0.10 (-0.10 to 0.40)	-0.05 ± 0.07 (-0.18 to 0.04)	-0.07 ± 0.05 (-0.18 to 0.02)	0.355
UIVA	monocular	0.62 ± 0.26 (0.20 to 1.24)	0.17 ± 0.06 (0.06 to 0.26)	0.19 ± 0.09 (0.00 to 0.36)	0.241
UIVA	binocular	0.40 ± 0.24 (0.10 to 1.04)	0.13 ± 0.05 (0.02 to 0.24)	0.13 ± 0.07 (0.00 to 0.24)	0.949
DCIVA	monocular	0.39 ± 0.16 (0.10 to 0.82)	0.25 ± 0.12 (0.00 to 0.56)	0.28 ± 0.07 (0.12 to 0.40)	0.217
DCIVA	binocular	0.26 ± 0.12 (0.06 to 0.62)	0.21 ± 0.05 (0.10 to 0.32)	0.24 ± 0.09 (0.10 to 0.38)	0.116

Supplemental Table 1

Journal of Cataract & Refractive Surgery®
Authorship Contribution Form

The Journal of Cataract & Refractive Surgery® follows the Uniform Requirements set out by the International Committee of Medical Journal Editors (www.icmje.org) for authorship. To qualify for authorship, each author must make a substantial contribution to the intellectual content of the manuscript in each of the following categories:

- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; **AND**
- Drafting the work or revising it critically for important intellectual content; **AND**
- Final approval of the version to be published; **AND**
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

The corresponding author is responsible for ensuring that all coauthors meet the requirements for authorship. Each author agrees that the corresponding author will be responsible for the submission of the manuscript to the JCRS and any associated activities. By submitting this manuscript, each of the authors indicates that he or she has had full access to all data in this study and takes complete and public responsibility for the integrity of the data and the accuracy of the data analysis. The issue of authorship must be resolved before submission of the manuscript. **All authors must sign this form, confirming he or she has made the contributions listed in the chart below.**

Please list all the manuscript authors and their contribution in the Contribution Table below. This form must be submitted with the original and any revised submission.

Article Title: Visual and Refractive Outcomes after Bilateral Implantation of an Enhanced Monofocal IOL: a Prospective study.

I have made substantive intellectual contributions to the content of this manuscript in the following areas:

Author Name	Concept and design	Data acquisition	Data analysis / interpretation	Drafting manuscript	Critical revision of manuscript	Statistical analysis	Securing funding	Admin, technical or material support	Supervision	Final approval
JAVIER GARCIA-BELLA	X	X	X		X				X	X
BARBARA BURGOS-BLASCO	X	X	X		X				X	X
BEATRIZ VIDAL-VILLEGAS	X	X	X		X				X	X
NURIA GARZON	X		X	X	X	X			X	X
CELIA VILLANUEVA	X	X	X		X				X	X
JULIAN GARCIA-FEIJOO	X	X	X		X				X	X

Other contributions:

(Please have all authors sign and date.)

1. Corresponding author CELIA VILLANUEVA

Signature of **corresponding** author: _____ Date Completed: 22/06/2023

2. Author JAVIER GARCIA-BELLA

Signature of author: _____ Date Completed: 22/06/2023

3. Author BARBARA BURGOS-BLASCO

Signature of author: _____ Date Completed: 22/06/2023

4. Author BEATRIZ VIDAL-VILLEGAS

Signature of author: _____ Date Completed: 22/06/2023

5. Author NURIA GARZON

Signature of author: _____ Date Completed: 22/06/2023

6 Author JULIAN GARCIA-FEIJOO

Signature of author: _____ Date Completed: 22/06/2023

7. Author _____

Signature of author: _____ Date Completed: _____

8 Author _____

Signature of author: _____ Date Completed: _____

9. Author _____

Signature of author: _____ Date Completed: _____

10. Author _____

Signature of author: _____ Date Completed: _____

11. Author _____

Signature of author: _____ Date Completed: _____

12. Author _____

Signature of author: _____ Date Completed: _____

If additional author and signature fields are needed, please duplicate this form as needed.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.